What is 3Spine?
Headquartered in Chattanooga, Tennessee, with specialized R&D hubs in the Greater Boston area, 3Spine operates as a vertically integrated healthcare entity. The company is dedicated to the development, clinical research, and delivery of total joint replacement solutions for the lumbar spine. Its flagship innovation, the MOTUS system, represents the culmination of two decades of rigorous design and clinical investigation. Unlike traditional fusion-based procedures that often limit patient mobility, the MOTUS technology is engineered to restore natural spinal balance and preserve range of motion. By controlling the entire value chain—from initial research to clinical delivery—3Spine maintains a unique market position that prioritizes patient outcomes and long-term biomechanical health over conventional surgical interventions.
How much funding has 3Spine raised?
3Spine has raised a total of $51.8M across 4 funding rounds:
Angel/Seed
$1.5M
Series A
$7.3M
Series B
$10M
Series C
$33M
Angel/Seed (2016): $1.5M, investors not publicly disclosed
Series A (2018): $7.3M, investors not publicly disclosed
Series B (2020): $10M, investors not publicly disclosed
Series C (2022): $33M featuring Byron DeFoor
Key Investors in 3Spine
Byron DeFoor
A private investor and strategic backer who has demonstrated a long-term commitment to the development of 3Spine's medical technology.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for 3Spine?
With the recent influx of capital, 3Spine is poised to scale its clinical operations significantly, particularly within its specialized facilities in the Cayman Islands. The strategic roadmap likely involves expanding the clinical application of the MOTUS system to a broader range of indications, thereby increasing its addressable market in the orthopedic sector. Furthermore, the company is expected to leverage its R&D infrastructure to refine its motion-enabling technology, potentially setting a new benchmark for lumbar joint replacement. As the firm moves into this mature phase of its lifecycle, the focus will shift toward long-term clinical data collection and the establishment of a robust commercial footprint, ensuring that its revolutionary approach to spinal health becomes a viable alternative to legacy surgical methods.
See full 3Spine company page
